Chiron, a Novartis business, announced today that it has agreed to extend and expand its blood screening collaboration with Gen-Probe until 2025. The companies will continue to work together to develop and commercialise molecular technologies that safeguard the world’s donated blood supply.
The collaboration between Novartis and Gen-Probe was established in 1998. It was previously scheduled to expire in 2013. Under the original terms of the agreement, the companies shared revenue from the sale of blood screening assays. Gen-Probe was responsible for manufacturing costs, while Novartis was responsible for commercial expenses. The companies shared research and development (R&D) costs.
“I am very pleased that our agreement with Gen-Probe has been extended until 2025. Nucleic acid testing is an important tool to safeguard the world’s blood supply against harmful pathogens,” said Peter Maag, global head of diagnostics, at Novartis Vaccines and Diagnostics.
“This renewed agreement with Gen-Probe provides a solid foundation that enables us to continue our expansion into the transfusion medicine market where we will provide innovative solutions to blood centers worldwide.”
To find out more about this collaboration please click on the link below: